Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
NCT02560753
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
T3D-959
Sponsor
T3D Therapeutics, Inc.